Inhibiting the renin-angiotensin system: Why and in which patients

Journal of the American Academy of Nurse Practitioners

Volumn 21, Issue 1, 2009, Pages 66-75

  Berra, Kathy ^a   Miller, Nancy Houston ^b  

^a Cardiovascular Medicine and Coronary Intervention   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Aliskiren; Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Diabetes; Heart failure; Nephropathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CASE MANAGEMENT; DRUG COMBINATION; DRUG EFFECT; EVIDENCE BASED PRACTICE; HUMAN; HYPERTENSION; NURSE PRACTITIONER; NURSING; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PHYSIOLOGY; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CASE MANAGEMENT; DRUG THERAPY, COMBINATION; EVIDENCE-BASED PRACTICE; HUMANS; HYPERTENSION; NURSE PRACTITIONERS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 58149384111     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2008.00374.x     Document Type: Article

References (82)

1. ACTIVE Steering Committee 2006). Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. American Heart Journal, 151, 1187 1193.
2. Acute Infarction Ramipril Efficacy Study Investigators 1993). Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 342, 821 828.
3. Aksnes, T. A., Kjeldsen, S. E., Rostrup, M., Omvik, P., Hua, T. A. Julius, S 2007). Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population. Hypertension, 50, 467 473.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group 2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association, 288, 2981 2997.
5. American Diabetes Association 2008). Standards of medical care in diabetes - 2008. Diabetes Care, 31 (Suppl. 1 S12 S54.
6. American Heart Association 2008). Heart disease and stroke statistics - 2008 update. Dallas, TX : Author.
7. Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., et al 2004). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - Executive summary. Journal of the American College of Cardiology, 44, 671 679.
8. Bakris, G. L. Clinical importance of microalbuminuria in diabetes and hypertension 2004). Current Hypertension Reports, 6, 352 356.
9. Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., et al for the Diabetics Exposed to Telmisartan and Enalapril Study Group 2004). Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. New England Journal of Medicine, 351, 1952 1961.
10. Berra, K., Miller, N. H. Fair, J. M 2006). Cardiovascular disease prevention and disease management: A critical role for nursing. Journal of Cardiopulmonary Rehabilitation, 26, 197 206.
11. Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., et al for the RENAAL Study Investigators 2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine, 345, 861 869.
12. Burnier, M. Brunner, H. R 2000). Angiotensin II receptor antagonists. Lancet, 355, 637 645.
13. Carson, P., Massie, B. M., McKelvie, R., McMurray, J., Komaida, M., Zike, M., et al for the I-PRESERVE Investigators 2005). The irbesartan heart failure with preserved systolic function (I-PRESERVE) trial: Rationale and design. Journal of Cardiac Failure, 11, 576 585.
14. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jr., et al 2003). Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206 1252.
15. Cohen, J. D 2007). Overview of physiology, vascular biology, and mechanisms of hypertension. Journal of Managed Care Pharmacy, 13 (Suppl S6 S8.
16. Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., et al 1991). A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine, 325, 303 310.
17. Cohn, J. N., Tognoni, G. for the Valsartan Heart Failure Trial Investigators 2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine, 345, 1667 1675.
18. Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., et al for the LIFE Study Group 2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet, 359, 995 1003.
19. de Zeeuw, D., Remuzzi, G., Parving, H. H., Keane, W. F., Zhang, Z., Shahinfar, S, et al 2004). Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation, 110, 921 927.
20. Diener, H. C., Sacco, R., Yusuf, S., Steering Committee PRoFESS Study Group 2007). Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases, 23, 368 380.
21. DREAM Trial Investigators 2006). Effect of ramipril on the incidence of diabetes. New England Journal of Medicine, 355, 1551 1562.
22. Estacio, R. O., Coll, J. R., Tran, Z. V. Schrier, R. W 2006). Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. American Journal of Hypertension, 19, 1241 1248.
23. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators 2003). Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 362, 782 788.
24. Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M., Hall, A., Murray, G., et al for the ACE-Inhibitor Myocardial Infarction Collaborative 2000). Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet, 355, 1575 1581.
25. Givertz, M. M 2001). Manipulation of the renin-angiotensin system. Circulation, 104, e14 e18.
26. Glasser, S. P 2000). On arterial physiology, pathophysiology of vascular compliance, and cardiovascular disease. Heart Disease, 2, 375 379.
27. Granger, C. B., McMurray, J. J. V., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., et al for the CHARM Investigators and Committees 2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet, 362, 772 776.
28. Grassi, G., Seravalle, G., Dell'Oro, R., Quarti Trevano, F., Bombelli, M., Scopelliti, F., et al 2003). Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. Journal of Hypertension, 21, 1761 1769.
29. Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R. Brancati, F. L. for the Atherosclerosis Risk in Communities Study 2000). Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. New England Journal of Medicine, 342, 905 912.
30. Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., et al for the Captopril Prevention Project (CAPPP) Study Group 1999). Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet, 353, 611 616.
31. Heart Outcomes Prevention Evaluation Study Investigators 2000a). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine, 342, 145 153.
32. Heart Outcomes Prevention Evaluation Study Investigators 2000b). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet, 355, 253 259.
33. HOPE Study Investigators 2000). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus; result of the HOPE and MICRO-HOPE substudy. Lancet, 355, 253 259.
34. Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., et al 2005). Guidelines update for the diagnosis and management of chronic heart failure in the adult. Journal of the American College of Cardiology, 46, 1 82.
35. Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., et al for the AIPRD Study Group 2003). Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Annals of Internal Medicine, 139, 244 252.
36. Kaschina, E. Unger, T 2003). Angiotensin AT1/AT2 receptors: Regulation, signaling and function. Blood Pressure, 12, 70 88.
37. Kilo, C., Taylor, A. Tschoepe, D 2006). Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes. European Heart Journal, 25 (Suppl 118. Abstract P789.
38. Klag, M. J., Whelton, P. K., Randall, B. L., Neaton, J. D., Brancati, F. L., Ford, C. H., et al 1996). Blood pressure and end stage renal disease in men. New England Journal of Medicine, 334, 13 18.
39. Lind, L., Pollare, T., Berne, C. Lithell, H 1994). Long-term metabolic effects of antihypertensive drugs. American Heart Journal, 128, 1177 1183.
40. Lindholm, L. H., Persson, M., Alaupovic, P., Carlberg, B., Svensson, A. Samuelsson, O 2003). Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). Journal of Hypertension, 21, 1563 1574.
41. Linz, W., Wohlfart, P., Schölkens, B. A., Malinski, T. Wiemer, G 1999). Interactions among ACE, kinins and NO. Cardiovascular Research, 43, 549 561.
42. Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B., et al for the SCOPE Study Group 2003). The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. Journal of Hypertension, 21, 875 886.
43. Maggioni, A. P., Anand, I., Gottlieb, S. O., Latini, R., Tognoni, G. Cohn, J. N. on behalf of the Val-HeFT Investigators 2002). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology, 40, 1414 1421.
44. Malmqvist, K., Kahan, T., Edner, M., Held, C., Hägg, A., Lind, L., et al on behalf of the investigators 2001) Regression of left ventricular hypertrophy in human hypertension with irbesartan. Journal of Hypertension, 19, 1167 1176.
45. Manjunath, G., Tighiouart, H., Ibrahim, H., MacLeod, B., Salem, D. N., Griffith, J. L., et al 2003). Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. Journal of the American College of Cardiology, 41, 47 55.
46. McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., et al 1999). Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation, 100, 1056 1064.
47. McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., et al for the CHARM Investigators and Committees 2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet, 362, 767 771.
48. Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., et al 2000). Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. British Medical Journal, 321, 1440 1444.
49. Moser, M., Rosendorff, C. White, W. B 2008). Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: Is there a difference in response and any advantage to using them together in the treatment of hypertension? Journal of Clinical Hypertension, 10, 485 492.
50. Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T. Ideura, T 2003). Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet, 361, 117 124.
51. National Kidney Foundation 2007). K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. American Journal of Kidney Diseases, 49 (Suppl S12 S154.
52. Olsen, M. H., Fossum, E., Høieggen, A., Wachtell, K., Hjerkinn, E., Nesbitt, D. D., et al 2005). Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. Journal of Hypertension, 23, 891 898.
53. ONTARGET Investigators 2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine, 358, 1547 1559.
54. ONTARGET/TRANSCEND Investigators 2004). Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal, 148, 52 61.
55. Opie, L. H. Schall, R 2004). Old antihypertensives and new diabetes. Journal of Hypertension, 22, 1453 1458.
56. Padwal, R. Laupacis, A 2004). Antihypertensive therapy and incidence of type 2 diabetes: A systematic review. Diabetes Care, 27, 247 255.
57. Parving, H. H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S. Arne, P. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group 2001). The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine, 345, 870 878.
58. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., et al for ADVANCE Collaborative Group 2007). Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet, 370, 829 840.
59. PEACE Trial Investigators 2004). Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine, 351, 2058 2068.
60. Phillips, C. O., Kashani, A., Ko, D. K., Francis, G. Krumholz, H. M 2007). Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left-ventricular dysfunction: A quantitative review of data from randomized clinical trials. Archives of Internal Medicine, 167, 1930 1936.
61. Pierson, C., Epstein, B. Roberts, M 2008). The importance of managing cardiovascular risk in the treatment of hypertension: The role of ACE inhibitors and ARBS. Journal of the American Academy of Nurse Practitioners, 20, 529 538.
62. Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., et al on behalf of the ELITE II Investigators 2000). Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II. Lancet, 355, 1582 1587.
63. Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., et al on behalf of ELITE Study Investigators 1997). Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet, 349, 747 752.
64. Pohl, M. A., Blumenthal, S., Cordonnier, D. J., De Alvaro, F., DeFerari, G., Eisner, G., et al for the Collaborative Study Group 2005). Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical implications and limitations. Journal of the American Society of Nephrology, 16, 3027 3037.
65. Prospective Studies Collaboration 2002). Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective trials. Lancet, 360, 1903 1913.
66. Ruggenenti, P., Perna, A., Loriga, G., Ganeva, M., Ene-Iordache, B., Turturro, M., et al for the REIN-2 Study Group 2005). Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet, 365, 939 946.
67. Schmieder, R. E., Delles, C., Mimran, A., Fauvel, J. P. Ruilope, L. M 2007). Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care, 30, 1351 1356.
68. Shafiq, M. M., Menon, D. V. Victor, R. G 2008). Oral direct renin inhibition: Premise, promise, and potential limitations of a new antihypertensive drug. American Journal of Medicine, 121, 265 271.
69. Shiuchi, T., Iwai, M., Li, H.-S., Wu, L., Min, L.-J., Li, J.-M., et al 2004). Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension, 43, 1003 1010.
70. Sica, D., Gradman, A. Lederballe, O 2006). Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCZ during long-term (52 weeks) treatment of hypertension. European Heart Journal, 25 (Suppl 121. Abstract P797.
71. Smith, S. C., Allen, J., Blair, S. N., Bonow, R. O., Brass, L. M, Fonarow, G. C., et al 2006). ACC/AHA guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular diseases. Journal of the American College of Cardiology, 47, 2130 2139.
72. SOLVD Investigators 1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine, 325, 293 302.
73. Taal, M. W. Brenner, B. M 2000). Renoprotective effects of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney International, 57, 1803 1817.
74. Tekturna (aliskiren) prescribing information 2007). East Hanover, NJ : Novartis Pharmaceutical.
75. Thürmann, P. A., Kenedi, P., Schmidt, A., Harder, S. Rietbrock, N 1998). Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation, 98, 2037 2042.
76. Unger, T 2002). The role of the renin-angiotensin system in the development of cardiovascular disease. American Journal of Cardiology, 89 (Suppl 3A 10A.
77. Verdecchia, P., Reboldi, G., Angeli, F., Borgioni, C., Gattobigio, R., Filippucci, L., et al 2004). Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension, 43, 963 969.
78. Viberti, G. Wheeldon, N. M. for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators 2002). Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation, 106, 672 678.
79. Weinberg, M. S., Weinberg, A. J. Zappe, D. H 2000). Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: Rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. Journal of the Renin-Angiotensin-Aldosterone System, 1, 217 233.
80. World Health Organization 2002). World Health Report, 2002: Reducing risks, promoting healthy life. Geneva, Switzerland : Author.
81. Wright, J. T., Jr., Bakris, G., Greene, T., Agodoa, L. Y., Appel, L. J., Charleston, J., et al for the African American Study of Kidney Disease and Hypertension Study Group 2002). Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. Journal of the American Medical Association, 288, 2421 2431.
82. Zhou, M. S., Schulman, I. H. Raij, L 2004). Nitric oxide, angiotensin II, and hypertension. Seminars in Nephrology, 24, 366 378.